Evidence map›Paper›PMID 32448216›Full record

SynthesisBMC infectious diseases2020

Prevalence and risk factors related to poor outcome of patients with severe Plasmodium vivax infection: a systematic review, meta-analysis, and analysis of case reports.

Manas Kotepui, Kwuntida Uthaisar Kotepui, Giovanni De Jesus Milanez, Frederick Ramirez Masangkay

Open access · goldAbstract readCase ReportsMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 13 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 13 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Procalcitonin as a Candidate Biomarker for Malarial Infection and Severe Malaria: A Meta-Analysis.International journal of environmental research and public health · 2022
    Pooled it
  5. Low Interleukin-12 Levels concerning Severe Malaria: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Malaria Infection and Risk for Endemic Burkitt Lymphoma: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2021
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Comparable severity ofNew microbes and new infections · 2026
    Article
  15. SevereClinical case reports · 2026
    Article
  16. Observational
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Manas KotepuiMedical Technology, School of Allied Health Sciences, Walailak University, Thasala, Nakhon Si Thammarat, Thailand. manas.ko@wu.ac.th.
Kwuntida Uthaisar KotepuiMedical Technology, School of Allied Health Sciences, Walailak University, Thasala, Nakhon Si Thammarat, Thailand.
Giovanni De Jesus MilanezDepartment of Medical Technology, Far Eastern University, Manila, Philippines.
Frederick Ramirez MasangkayDepartment of Medical Technology, Far Eastern University, Manila, Philippines.
Far Eastern University · PHWalailak University · TH

Funding

Walailak University the new strategic research (P2P) project
6 · The paper itself

Abstract

backgroundPlasmodium vivax rarely develops severe complications when compared to severe falciparum malaria. However, severe vivax malaria also needs urgent, intensive care and treatment as severe falciparum malaria. This systematic review aimed to explore pooled prevalence of severe vivax malaria and to identify factors related to poor outcome of patients who developed severe manifestation.

methodsThe systematic review conducted by two reviewers independently through searching of research publications related to severe P. vivax malaria in three databases including MEDLINE, Web of Science (ISI), and Scopus until October, 22 2019. The pooled prevalence of severe vivax malaria was achieved using STATA and RevMan 5 Software. Factors related to poor outcome of patients with severe vivax malaria were analyzed using SPSS 11.5 Software.

resultsAmong 2615 research publications retrieved from three databases, 49 articles reporting on 42,325 severity cases were selected for calculating pooled prevalence. Seventy-six patients from case reports, case series, letter to editors, and research communications were collected to identify factors related to poor outcome of patients with severe vivax malaria. The results showed that severe anemia, jaundice, respiratory distress, impaired consciousness, and renal failure were the most common major manifestations of severe malaria guided by the World Health Organization (WHO) criterion. The meta-analysis indicated that severe malaria was less frequent in patient with P. vivax compared to those with P. falciparum (P -value < 0.00001, OR = 0.38, 95% CI = 0.25-0.56, I

conclusionsSevere anemia was the most common major manifestation of P. vivax malaria guided by the WHO criterion. Severe anemia was found less frequently in patients with P. vivax than those with P. falciparum. Renal failure, jaundice, anuria/oliguria, and complication during treatment along with, mean days of fever and higher pulse rates at presentation might be predictors of poor outcome of patients with severe vivax malaria.

Indexed as

Plasmodium falciparumPlasmodium vivaxSeverity of Illness IndexAdultAnemiaAntimalarialsAnuriaFemaleFeverHeart RateHumansJaundiceMalaria, FalciparumMalaria, VivaxMaleOliguriaAntimalarialsDischargePoor outcomeP. vivaxSevere malariaTreatment outcome

Identifiers

PMID32448216
PMCPMC7245863
OpenAlexW3027409049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.